Signpath Pharma Competitors and Similar CompaniesClear all

Signpath Pharma's competitors and similar companies include Nektar Therapeutics, CureVac and Exelixis.

	Signpath Pharma SignPath Pharma is a biotechnology company that develops products to treat cancer and mitigate drug-induced cardiac arrhythmia.	Nektar Therapeutics Nektar Therapeutics is a stage-clinical biopharmaceutical company.	CureVac CureVac is a biotechnology company offering messenger RNA (mRNA) technology.	Exelixis Exelixis is an oncology company that develops cancer treatments.
Founding Date	Founding Date 2006	Founding Date 1990	Founding Date 2000	Founding Date 1994
Type	Type Private	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma
Locations	Locations Sandy, US HQ	Locations San Francisco, US HQ Hyderabad, IN Huntsville, US	Locations Tübingen, DE HQ Ottignies Louvain La Neuve, BE Wiesbaden, DE Amsterdam, NL Basel, CH Boston, US	Locations Alameda, US HQ
Employees	Employees 11	Employees 61821% increase	Employees 82517% decrease	Employees 1,14712% decrease
Valuation ($)	Valuation ($) N/A	Valuation ($) 233.8 m	Valuation ($) 648.3 m	Valuation ($) 8.2 b
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $55.2m (FY, 2025)	Revenue (est.) €535.2m (FY, 2024)	Revenue (est.) $2.3b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods €9.7m (FY, 2024)	Cost of goods $83.7m (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit €534.4m (FY, 2024)	Gross profit $2.2b (FY, 2025)
Net income	Net income N/A	Net income ($164.1m) (FY, 2025)	Net income €162.2m (FY, 2024)	Net income $782.6m (FY, 2025)
Funding
Total funding raised	Total funding raised $ 5.3m	Total funding raised $ 45m	Total funding raised $ 1.1b	Total funding raised N/A